What Maverex does

Maverex Limited is a privately-held health economics and outcomes research (HEOR) and market access consultancy headquartered in Newcastle upon Tyne, United Kingdom, with a registered office in London. Founded in 2016, the firm employs over 35 specialists with backgrounds spanning health economics, market access, statistics, and epidemiology, and serves global pharmaceutical and medical technology companies. Its operating model is professional services: project-based, quote-priced consulting engagements delivered by cross-functional teams, with most business conducted on a repeat basis through multi-year contracts.

The firm's service portfolio comprises seven integrated practices: Global Market Access Strategy, Real World Evidence, Environmental Sustainability Assessments, Health Economic Modelling, HTA Support, Value Communications, and Evidence Synthesis (including literature reviews, meta-analyses, and statistical support). Underlying technology is grounded in established HEOR and Health Technology Assessment methodologies — cost-effectiveness analysis, cost-consequence analysis, budget impact modelling, and systematic evidence synthesis — rather than proprietary software platforms. The differentiating technical capability is an industry-leading environmental sustainability assessment methodology that quantifies emissions and resource use driven by treatment choices and patient pathways, positioning Maverex at the intersection of HEOR and ESG advisory. The firm supports engagements across the product lifecycle, from pre-clinical Phase I through lifecycle management.

Maverex generates revenue through custom, project-based fees billed against multi-year contracts with enterprise clients. Its go-to-market is enterprise field sales targeting Top 5 and Top 20 global biopharma, Fortune 500 pharmaceutical and medical device companies, and select startup biopharma. Delivery is structured to support clients across EMEA, Americas, and APAC. Maverex Limited is founder-owned, with no disclosed funding rounds, no parent company, no acquisitions, and no subsidiaries. The firm holds Women Owned certification and has obtained Science Based Targets initiative (SBTi) approval of its near-term science-based emissions reduction target, aligning its own ESG posture with the advisory area in which it is positioning as a market leader.

Name

Maverex

Legal name

Maverex Limited

Website

https://maverex.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Maverex is a UK-based HEOR and market access consultancy employing 35+ specialists to deliver health economic modelling, HTA support, real-world evidence, value communications, and environmental sustainability assessments to global pharmaceutical and medical technology companies.

Ownership category

akta.pro rank

Headquarters

HQ city

Newcastle Upon Tyne

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Consulting Services: Professional consulting services provided to global Pharma and MedTech companies for market access strategy, HTA support, real world evidence, value communications, and environmental sustainability assessments. Revenue generated through project-based consulting engagements.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Maverex is a HEOR and market access consultancy that provides strategic consulting services to global pharmaceutical, medical device, and diagnostic companies. Its core offering is an integrated suite of services spanning the product lifecycle — including global market access strategy, real world evidence, environmental sustainability assessments, health economic modelling, HTA submission support, value communications, and evidence synthesis. The firm is recognised as an industry leader in environmental sustainability assessments for healthcare products and care pathways.

Product overview

Maverex is a HEOR and market access consultancy that offers a unified suite of services rather than a traditional software product platform. Their core offerings include Global Market Access Strategy, Real World Evidence, Environmental Sustainability Assessments, Economic Modelling, HTA Support, Value Communications, and Evidence Synthesis. These services work together as an integrated consultancy offering, with specialized cross-functional teams providing strategic insight grounded in extensive experience to help global Pharma and MedTech companies achieve market access and deliver innovation to patients worldwide. The company is particularly noted as an industry leader in environmental sustainability assessments for healthcare products and care pathways.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Market Access Strategy Strategic market access consulting to help pharmaceutical and MedTech companies achieve optimal reimbursement and formulary positioning across global markets, spanning pre-clinical, pivotal, pre-launch, early commercialisation, and lifecycle management phases.
• Real World Evidence Collection and analysis of real-world data to support market access, health economics, and regulatory decisions for pharmaceutical and MedTech clients.
• Environmental Sustainability Assessments Industry-leading assessments of environmental emissions and resource use driven by treatment choices and patient pathways, helping payers and policymakers meet sustainability goals.
• Economic Modelling Health economic modelling services including cost-effectiveness analysis, cost-consequence analysis, and budget impact models across therapeutic areas such as oncology, cardiovascular, respiratory, and autoimmune diseases, built for HTA submissions.
• HTA Support Health Technology Assessment submission support including evidence synthesis, dossier preparation, and engagement with HTA bodies for pharmaceutical and MedTech clients.
• Value Communications Development and articulation of value propositions and evidence packages for regulators, HTA bodies, payers, and other stakeholders.
• Evidence Synthesis Literature reviews, meta-analyses, and statistical support services to synthesise clinical and economic evidence for market access and HTA purposes.

Quantifiable outcome

• Distribution of take-home naloxone decreased overdose deaths by around 6.6% and was cost-effective with incremental cost per QALY gained of £899
• +1 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Science Based Targets initiative (SBTi)coreStrategic or Co-development PartnerMaverex has an SBTi-approved near-term science-based emissions reduction target. This partnership demonstrates Maverex's commitment to environmental sustainability and positions them as leaders in integrating environmental evidence in market access and policy strategy.

Scale indicators1 record

Recent moves5 records

Expansion highlights6 records

Emerging players

• Maple Health Group: Smaller HEOR and market access consultancy serving pharma clients with evidence synthesis and HTA support — comparable niche positioning at an earlier scale stage.

Direct peers

• Mtech Access: UK-based health economics and market access consultancy offering similar HEOR, HTA, and value communication services to pharma and MedTech clients. Most direct comparable by size, geography, and service mix.
• Cogentia Healthcare Consulting: UK-headquartered market access and HEOR consultancy serving pharma and medical device companies with pricing, reimbursement, and HTA submission support — directly comparable niche competitor.
• Envision Pharma Group: Global medical communications and HEOR/market access consultancy serving pharma clients across the product lifecycle. Comparable service portfolio with broader scale.
• Valid Insight: Specialist market access and HEOR consultancy providing evidence synthesis, value communications, and HTA support to pharma and biotech — a similar niche player in the same service categories.
• RTI Health Solutions: Specialized HEOR, market access, and real-world evidence consultancy within RTI International, serving pharma and MedTech with comparable deliverables (economic modelling, evidence synthesis, HTA support).

Broad incumbents

• Evidera: Large HEOR and market access consultancy (part of Thermo Fisher's PPD) offering the full suite of services Maverex provides plus broader real-world evidence, epidemiology, and clinical outcomes — a much larger, established competitor.
• IQVIA: Global leader in life sciences data, technology, and consulting, with a substantial HEOR and market access practice. Provides overlapping capabilities at significantly greater scale and geographic reach than Maverex.
• Charles River Associates (Life Sciences Practice): Global consulting firm with a life sciences practice offering HEOR, pricing, and market access strategy. Overlaps with Maverex's strategic consulting offering but as part of a broader portfolio.

Others

• Health Economics Consulting (HEC) at Pharmaprojects / GlobalData: Provides market access data, analytics, and HEOR research to pharma clients — thematically adjacent as both serve the same buyer function for evidence-based market access decisions.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/maverex-limited
• Xx.com/MaverexHEOR

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maverex